1. Owen, M.J., O’Donovan, M.C., and Gottesman, I.I. 2002. Schizophrenia. In Psychiatric genetics and genomics. P. McGuffin, M.J. Owen, and I.I. Gottesman, editors. Oxford University Press. New York, New York, USA. 247–266.
2. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry. 2002;47:833–843. [PubMed] 3. Riley BP, McGuffin P. Linkage and associated studies of schizophrenia. Am. J. Med. Genet. 2000;97:23–44. [PubMed] 4. Sklar P. Linkage analysis in psychiatric disorders: the emerging picture. Annu. Rev. Genomics Hum. Genet. 2002;3:371–413. [PubMed] 5. Lewis CM, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am. J. Hum. Genet. 2003;73:34–48. [PubMed] 6. O’Donovan MC, Williams NM, Owen MJ. Recent advances in the genetics of schizophrenia. Hum. Mol. Genet. 2003;12:R125–R133. [PubMed] 7. Owen MJ, Williams NM, O’Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry. 2004;9:14–27. [PubMed] 8. Cloninger CR. The discovery of susceptibility genes for mental disorders. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13365–13367. [PubMed] 9. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathological implications. Lancet. 2003;361:417–419. [PubMed] 10. Straub RE, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 2002;71:337–348. [PubMed]
11. Datta, S.R., et al. 2003. Tests of linkage disequilibrium between schizophrenia and genetic markers at the G72 and dysbindin loci. Presentation at: XIth World Congress of Psychiatric Genetics. October 4–8. Quebec City, Quebec, Canada.
12. van den Oord EJCG, et al. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol. Psychiatry. 2003;8:499–510. [PubMed] 13. Williams NM, et al. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1) Arch. Gen. Psychiatry. 2004;61:336–344. [PubMed]
14. Bakker SC, et al. Association study of the neuregulin, dysbindin and G72 genes in a large sample of Dutch schizophrenic patients. Am. J. Med. Genet. 2003;122B:19. (Abstr.)
15. Schwab SG, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 2003;72:185–190. [PubMed] 16. Van Den Bogaert A, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet. 2003;73:1438–1443. [PubMed] 17. Kirov, G., et al. 2004. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol. Psychiatry. In press.
[PubMed] 18. Tang JX, et al. Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol. Psychiatry. 2003;8:717–718. [PubMed]
19. Shi YY, et al. Non-family based association study of DTNBP1 in 6p22.3 and schizophrenia in geographically and genetically structured Chinese Han population. Am. J. Med. Genet. 2003;122B:102. (Abstr.)
20. Yamada K, et al. Suggestive evidence of association between the DTNBP1 gene and schizophrenia in the Japanese samples. Am. J. Med. Genet. 2003;122B:131.
21. Morris DW, et al. No evidence for association of the dysbindin gene (DTNBP1) with schizophrenia in an Irish population-based study. Schizophr. Res. 2003;60:167–172. [PubMed] 22. Maier W, Zobel A, Rietschel M. Genetics of schizophrenia and affective disorders. Pharmacopsychiatry. 2003;36(Suppl. 3):5195–5202. [PubMed]
23. McClintock, B.W., et al. 2002. Reduced expression of the common dysbindin transcript in the dorsolateral cortex of schizophrenics. Presentation at: 41st Annual Meeting of the American College of Neuropsychopharmacology. December 8–12. San Juan, Puerto Rico, USA.
24. Straub RE, et al. Dysbindin protein is decreased in the dorsolateral prefrontal cortex of schizophrenia patients. Biol. Psychiatry. 2004;55(Suppl. 1):116S. (Abstr.)
25. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 2001;276:24232–24241. [PubMed] 26. Li W, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1) Nat. Genet. 2003;35:84–89. [PMC free article] [PubMed] 27. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002;82:291–329. [PubMed] 28. Lidov HGW. Dystrophin in the nervous system. Brain Pathol. 1996;6:63–77. [PubMed] 29. Blake DJ, Hawkes R, Benson MA, Beesley PW. Different dystrophin-like complexes are expressed in neurons and glia. J. Cell Biol. 1999;147:645–657. [PMC free article] [PubMed] 30. Blake DJ, Nawrotzki R, Loh NY, Górecki DC, Davies KE. β-Dystrobrevin, a member of the dystrophin-related protein family. Proc. Natl. Acad. Sci. U. S. A. 1998;95:241–246. [PubMed] 31. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res. Rev. 2000;31:251–269. [PubMed] 32. Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001;24:479–486. [PubMed] 33. Bray NJ, Buckland PR, Owen MJ, O’Donovan MC. Cis-acting variation in the expression of a high proportion of genes in human brain. Hum. Genet. 2003;113:149–153. [PubMed] 34. Lederhendler I, Schulkin J. Behavioral neuroscience: challenges for the era of molecular biology. Trends Neurosci. 2000;23:451–454. [PubMed] 35. Knuesel I, et al. Altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice) Eur. J. Neurosci. 1999;11:4457–4462. [PubMed] 36. Brünig I, Suter A, Knuesel I, Lüscher B, Fritschy J-M. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABAA receptors and gephyrin. J. Neurosci. 2002;22:4805–4813. [PubMed] 37. Harrison PJ, Eastwood SL. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus. 2001;11:508–519. [PubMed]
38. Dwork, A.J. 2002. Post mortem studies of the hippocampal formation in schizophrenia. In The postmortem brain in psychiatric research. G. Agam, I.P. Everall, and R.H. Belmaker, editors. Kluwer Academic Publishers. Boston, Massachusetts, USA. 253–266.
39. Schmajuk NA. Hippocampal dysfunction in schizophrenia. Hippocampus. 2001;11:599–613. [PubMed] 40. Arnold SE, et al. Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am. J. Psychiatry. 1995;152:731–737. [PubMed] 41. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 2000;44:151–155. [PubMed] 42. Maddox PH, Jenkins D. 3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. J. Clin. Pathol. 1987;40:1256–1260. [PMC free article] [PubMed] 43. Kaneko T, Fujiyama F, Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J. Comp. Neurol. 2002;444:39–62. [PubMed] 44. Pileri SA, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol. 1997;183:116–123. [PubMed] 45. Teclemariam-Mesbah R, Wortel J, Romijn HJ, Buijs RM. A simple silver-gold intensification procedure for double DAB labeling studies in electron microscopy. J. Histochem. Cytochem. 1997;45:619–621. [PubMed] 46. Siegel SJ, et al. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 2002;26:817–823. [PubMed] 47. Scharfman HE, Witter MP, Schwarcz R. The parahippocampal region: implications for neurological and psychiatric diseases. Introduction. Ann. N. Y. Acad. Sci. 2000;911:ix–xiii. [PubMed]
48. Insausti, R., and Amaral, D.G. 2004. Hippocampal formation. In The human nervous system. 2nd edition. G. Paxinos and J. Mai, editors. Academic Press. New York, New York, USA. 871–914.
49. Witter, M.P., and Amaral, D.G. 2004. Hippocampal region. In The rat nervous system. 3rd edition. G. Paxinos, editor. Academic Press. New York, New York, USA.
50. Kapur S, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 1997;131:148–152. [PubMed] 51. Walker MA, et al. Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am. J. Psychiatry. 2002;159:821–828. [PubMed]
52. Gornick, M., et al. 2003. Polymorphisms in dysbindin (DTNBP1, 6p22.3) are associated with intermediate phenotypes measured by the Premorbid Adjustment Scale (PAS) in cases of childhood onset psychosis. 53rd Annual Meeting of the American Society of Human Genetics. November 4–8. Los Angeles, California, USA. (Abstr.)
53. Huard J, Côté P-Y, Parent A, Bouchard J-P, Tremblay JP. Dystrophin-like immunoreactivity in monkey and human brain areas involved in learning and motor functions. Neurosci. Lett. 1992;141:181–186. [PubMed] 54. Dawirs RR, Teuchert-Noodt G, Hildebrandt K, Fei F. Granule cell proliferation and axon terminal degradation in the dentate gyrus of gerbils (Meriones unguiculatus) during maturation, adulthood and aging. J. Neural Transm. 2000;107:639–647. [PubMed] 55. Eastwood SL, et al. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 1995;29:211–223. [PubMed] 56. Porter RHP, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 1997;751:217–231. [PubMed] 57. Law AJ, Deakin JFW. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 2001;12:2971–2974. [PubMed] 58. Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 2003;97:153–179. [PubMed] 59. Collier DA, Li T. The genetics of schizophrenia: glutamate not dopamine? Eur. J. Pharmacol. 2003;480:177–184. [PubMed] 60. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003;40:881–884. [PubMed] 61. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. Mol. Med. 2003;9:3–9. [PMC free article] [PubMed] 62. Hetherington PA, Austin KB, Shapiro ML. Ipsilateral associational pathway in the dentate gyrus: an excitatory feedback system that supports N-methyl-D-aspartate-dependent long-term potentiation. Hippocampus. 1994;4:422–438. [PubMed] 63. Jackson MB, Scharfman HE. Positive feedback from hilar mossy cells to granule cells in the dentate gyrus revealed by voltage-sensitive dye and microelectrode recording. J. Neurophysiol. 1996;76:601–616. [PubMed] 64. Wenzel HJ, Buckmaster PS, Anderson NL, Wenzel ME, Schwartzkroin PA. Ultrastructural localization of neurotransmitter immunoreactivity in mossy cell axons and their synaptic targets in the rat dentate gyrus. Hippocampus. 1997;7:559–570. [PubMed] 65. Witter MP, Wouterlood FG, Naber PA, van Haeften T. Anatomical organization of the parahippocampal-hippocampal network. Ann. N. Y. Acad. Sci. 2000;911:1–24. [PubMed] 66. Scharfman HE. Dentate hilar cells with dendrites in the molecular layer have lower thresholds for synaptic activation by perforant path than granule cells. J. Neurosci. 1991;11:1660–1673. [PubMed] 67. Sik A, Pentonnen M, Buzsáki G. Interneurons in the hippocampal dentate gyrus: an in vivo intracellular study. Eur. J. Neurosci. 1997;9:573–588. [PubMed] 68. Vizi ES, Kiss JP. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. Hippocampus. 1998;8:566–607. [PubMed] 69. Ishizuka N, Weber J, Amaral DG. Organization of intrahippocampal projections originating from CA3 pyramidal cells in the rat. J. Comp. Neurol. 1990;295:580–623. [PubMed] 70. Nakazawa K, et al. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 2002;297:211–218. [PMC free article] [PubMed] 71. Petrozzino JJ, Connor JA. Dendritic Ca2+ accumulation and metabotropic glutamate receptor activation associated with an N-methyl-D-aspartate receptor-independent long-term potentiation in hippocampal CA1 neurons. Hippocampus. 1994;4:546–558. [PubMed] 72. Small SA. The longitudinal axis of the hippocampal formation: its anatomy, circuitry, and role in cognitive function. Rev. Neurosci. 2002;13:183–194. [PubMed] 73. Lisman JE. Relating hippocampal circuitry to function: recall of memory sequences by reciprocal dentate-CA3 interactions. Neuron. 1999;22:233–242. [PubMed]
74. Gur, R.C., Moelter, S.T., and Ragland, J.D. 2000. Learning and memory in schizophrenia. In Cognition in schizophrenia: impairments, importance, and treatment strategies. T. Sharma and P. Harvey, editors. Oxford University Press. New York, New York, USA. 73–91.
75. Goldberg, T.E., David, A., and Gold, J.M. 2003. Neurocognitive deficits in schizophrenia. In Schizophrenia. 2nd edition. S.R. Hirsch and D.R. Weinberger, editors. Blackwell Publishing. Malden, Massachusetts, USA. 168–184.